This Article Full Text Full Text (PDF) All Versions of this Article: 1/5/337    most recent CIRCEP.108.795351v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okin, P. M. Articles by Devereux, R. B. Search for Related Content PubMed Articles by Okin, P. M. Articles by Devereux, R. B. Related Collections Epidemiology Hypertrophy Electrocardiology Clinical Studies Related Articles

Original Articles

Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients

The LIFE Study

Peter M. Okin, MD; Kristian Wachtell, MD, PhD; Sverre E. Kjeldsen, MD, PhD; Stevo Julius, MD, ScD; Lars H. Lindholm, MD, PhD; Björn Dahlöf, MD, PhD; Darcy A. Hille, MSEM, BA; Markku S. Nieminen, MD; Jonathan M. Edelman, MD and Richard B. Devereux, MD

From the Greenberg Division of Cardiology (P.M.O., R.B.D.), Weill Cornell Medical College, New York, NY; The Heart Center (K.W.), Rigshospitalet, Copenhagen, Denmark; Department of Internal Medicine, University of Oslo (S.E.K.), Ullevål Hospital, Oslo, Norway; Department of Medicine, University of Michigan Medical Center (S.E.K., S.J.), Ann Arbor, Mich; Department of Internal Medicine, Umeå University (L.H.L.), Umeå, Sweden; Department of Internal Medicine, Sahlgrenska University Hospital/Östra (B.D.), Göteborg, Sweden; Merck Research Labs (D.A.H.), West Point, Pa; Division of Cardiology (M.S.N.), Department of Medicine, Helsinki University Central Hospital, Finland; and Merck & Co Inc (J.M.E.), North Wales, Pa.

Correspondence to Peter M. Okin, MD, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10065. E-mail pokin{at}med.cornell.edu

Received May 29, 2008; accepted August 21, 2008.

Background— Onset of atrial fibrillation (AF) has been linked to changes in autonomic tone, with increasing heart rate (HR) immediately before AF onset in some patients suggesting a possible role of acute increases in sympathetic activity in AF onset. Although losartan therapy and decreasing ECG left ventricular hypertrophy are associated with decreased AF incidence, the relationship of HR changes over time to development of AF has not been examined.

Methods and Results— HR was evaluated in 8828 hypertensive patients without AF by history or on baseline ECG in the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. Patients were treated with losartan- or atenolol-based regimens and followed with serial ECGs annually which were used to determine HR and ECG left ventricular hypertrophy by Cornell product and Sokolow-Lyon voltage criteria. During mean follow-up of 4.7±1.1 years, new-onset AF occurred in 701 patients (7.9%). Patients with new AF had smaller decreases in HR to last in-treatment ECG or last ECG before AF (–2.7±13.5 versus –5.2±12.5 bpm), whether on losartan- (–0.4±13.5 versus –2.2±11.7 bpm) or atenolol-based treatment (–5.3±12.8 versus –8.3±12.6 bpm, all P<0.001). In univariate Cox analyses, higher HR on in-treatment ECGs was associated with an increased risk of new-onset AF, with a 15% greater risk of AF for every 10 bpm higher HR (95% CI 8% to 22%). In alternative analyses, persistence or development of a HR84 (upper quintile of baseline HR) was associated with a 46% greater risk of developing AF (95% CI 19% to 80%). After adjusting for treatment with losartan versus atenolol, baseline risk factors for AF, baseline and in-treatment systolic and diastolic pressure and the known predictive value of baseline and in-treatment ECG left ventricular hypertrophy for new AF, higher in-treatment HR remained strongly associated with new AF with a 19% higher risk for every 10 bpm higher HR (95% CI 10% to 28%) or a 61% increased rate of AF in patients with persistence or development of a HR84 (95% CI 27% to 104%, all P<0.001).

Conclusion— Higher in-treatment HR on serial ECGs is associated with an increased likelihood of new-onset AF, independent of treatment modality, blood pressure lowering, and regression of ECG left ventricular hypertrophy in patients with essential hypertension.

Key Words: electrocardiography • fibrillation • heart rate • hypertension • hypertrophy

---

 

CLINICAL PERSPECTIVE

Related Articles

Slower Heart Rates for Healthy Hearts: Time to Redefine Tachycardia?

Rakesh Gopinathannair, Renee M. Sullivan, and Brian Olshansky
Circ Arrhythmia Electrophysiol 2008 1: 321-323. [Extract] [Full Text] [PDF]

Chronic Atrial Fibrillation Is a Biatrial Arrhythmia: Data from Catheter Ablation of Chronic Atrial Fibrillation Aiming Arrhythmia Termination Using a Sequential Ablation Approach

Thomas Rostock, Daniel Steven, Boris Hoffmann, Helge Servatius, Imke Drewitz, Karsten Sydow, Kai Müllerleile, Rodolfo Ventura, Karl Wegscheider, Thomas Meinertz, and Stephan Willems
Circ Arrhythmia Electrophysiol 2008 1: 344-353. [Abstract] [Full Text] [PDF]

ECG Quantification of Myocardial Scar in Cardiomyopathy Patients With or Without Conduction Defects: Correlation With Cardiac Magnetic Resonance and Arrhythmogenesis

David G. Strauss, Ronald H. Selvester, João A.C. Lima, Håkan Arheden, Julie M. Miller, Gary Gerstenblith, Eduardo Marbán, Robert G. Weiss, Gordon F. Tomaselli, Galen S. Wagner, and Katherine C. Wu
Circ Arrhythmia Electrophysiol 2008 1: 327-336. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				R. Gopinathannair, R. M. Sullivan, and B. Olshansky Slower Heart Rates for Healthy Hearts: Time to Redefine Tachycardia? Circ Arrhythmia Electrophysiol, December 1, 2008; 1(5): 321 - 323. [Full Text] [PDF]